Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations

被引：47

作者：

Coulson, A. ^{[1
]}

Levy, A. ^{[1
]}

Gossell-Williams, M. ^{[1
]}

机构：

[1] Univ W Indies, Dept Basic Med Sci, Pharmacol Sect, Kingston 7, Jamaica

来源：

WEST INDIAN MEDICAL JOURNAL | 2014年 / 63卷 / 06期

关键词：

Antigenic targets; cancer therapy; clinical benefits; monoclonal antibodies; CHRONIC LYMPHOCYTIC-LEUKEMIA; BRENTUXIMAB VEDOTIN; COLORECTAL-CANCER; LYMPHOMA; RITUXIMAB; CHEMOTHERAPY; RADIOIMMUNOTHERAPY; TRASTUZUMAB; BEVACIZUMAB; INDUCTION;

D O I：

10.7727/wimj.2013.241

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin's lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers. In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.

引用

页码：650 / 654

页数：5

共 50 条

[41] Recent developments in colorectal cancer treatment by monoclonal antibodies [J].

Arsene, Dominique ;

Galais, Marie-Pierre ;

Bouhier-Leporrier, Karine ;

Reimund, Jean-Marie .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (11) :1175-1192

[42] rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in cancer therapy [J].

Dong, Wenliang ;

Chen, Min ;

Wang, Jiaxue ;

Xia, Lin ;

Wang, Qian ;

Nie, Xiaoyan ;

Feng, Yufei ;

Fang, Yi .

IMMUNOTHERAPY, 2021, 13 (01) :79-88

[43] Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy [J].

Riller, Quentin ;

Varthaman, Aditi ;

Siberil, Sophie .

TUMOR MICROENVIRONMENT: MOLECULAR PLAYERS, PT B, 2020, 1277 :127-141

[44] Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies? [J].

Mohammad Reza Zamani ;

Pavel Šácha .

Medical Oncology, 42 (7)

[45] Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy [J].

Martinelli, E. ;

De Palma, R. ;

Orditura, M. ;

De Vita, F. ;

Ciardiello, F. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 158 (01) :1-9

[46] Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates [J].

Khiavi, Mostafa Akbarzadeh ;

Safary, Azam ;

Somi, Mohammad Hossein .

BIOIMPACTS, 2019, 9 (03) :123-127

[47] Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies [J].

Zhu, H ;

Baxter, LT ;

Jain, RK .

JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) :731-741

[48] The role of monoclonal antibodies in the treatment of lymphomas [J].

Hsu, Jack W. ;

Dang, Nam H. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (02) :227-239

[49] Monoclonal antibodies in head and neck cancer [J].

vanDongen, GAMS ;

Brakenhoff, RH ;

vanGog, FB ;

deBree, R ;

Quak, JJ ;

Snow, GB .

HEAD AND NECK CANCER - ADVANCES IN BASIC RESEARCH, 1996, 1114 :555-567

[50] Update on monoclonal antibodies for the treatment of cancer [J].

Davis, Ian D. .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 :20-25

← 1 2 3 4 5 →